Safety Reading Notes

Read safety context beside the research guide.

The CB2 receptor immune/inflammation source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 39334169

PubMed For Dummies Article

CB2 receptor immune/inflammation Evidence Review: the long-form source walk-through

Quick read
  • CB2 receptor immune/inflammation currently has 31 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 39334169
  • The evidence classes most visible in the row language are mechanistic or pharmacological (23), and insufficient (8). PMID 19152719
  • The study-design language most visible in the row language is Animal study (18), Narrative or expert review (8), and Cellular or in vitro study (4). PMID 38662453
  • The repeated topics are CB2 (31), which tells the reader where to start opening PubMed and DOI links. PMID 22197668

Start with the research question

CB2 receptor immune/inflammation is built from 31 source-backed evidence row(s) and 31 research source(s). The current evidence classes read as mechanistic or pharmacological (23), and insufficient (8), and the study-design language most often reads as Animal study (18), Narrative or expert review (8), and Cellular or in vitro study (4). PMID 39334169

The row-level question is not simply whether CB2 receptor immune/inflammation is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are CB2 (31). PMID 19152719

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 39173999

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 39264450

Mechanistic evidence 23 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 36475439

Limits and uncertainty 8 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 37061199

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 18615177

Where this page has the most source density

The largest bucket surfaced for this page is CB2: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is CB2: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 39334169

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 19152719

Bucket chapters: what the literature is circling

CB2: mechanistic or pharmacological

23 research sources 23 rows (895-925) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on CB2: mechanistic or pharmacological. It currently draws from 23 research source(s), so the exact study type matters. PMID 39334169

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 39334169

  • Evidence row 895

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain... PMID 39334169

  • Evidence row 925

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, mic... PMID 41740200

CB2: insufficient

8 research sources 8 rows (896-923) Evidence class: insufficient

This bucket summarizes source-backed rows focused on CB2: insufficient. It currently draws from 8 research source(s), so the exact study type matters. PMID 19152719

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 19152719

  • Evidence row 896

    Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 19152719

  • Evidence row 923

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinfl... PMID 32471272

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (23 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 39334169

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 19152719

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 30666359
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 29794855
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 37286073

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 39334169

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 19152719

Source-reading checklist for CB2 receptor immune/inflammation

  1. Open the linked PubMed or DOI record. PMID 26824325
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 23960212
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 38751621
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 20236042
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 12823482

Source Notes

CB2 receptor immune/inflammation source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 895

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39334169

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy.
  2. Evidence row 896

    Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 19152719

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.
  3. Evidence row 897

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 38662453

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease.
  4. Evidence row 898

    Cannabinoids modulates CB2; evidence class: insufficient (study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 22197668

    Evidence class: insufficient; Study design: Narrative or expert review. Source: CB₂: therapeutic target-in-waiting.
  5. Evidence row 899

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39173999

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation.
  6. Evidence row 900

    Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39264450

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.
  7. Evidence row 901

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 36475439

    Evidence class: mechanistic or pharmacological. Source: Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation.
  8. Evidence row 902

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 37061199

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice.
  9. Evidence row 903

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18615177

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration.
  10. Evidence row 904

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 30666359

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice.
  11. Evidence row 905

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 29794855

    Evidence class: insufficient; Study design: Narrative or expert review. Source: An overview of the cannabinoid type 2 receptor system and its therapeutic potential.
  12. Evidence row 906

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 37286073

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.
  13. Evidence row 907

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 26824325

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2.
  14. Evidence row 908

    Endocannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 23960212

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice.
  15. Evidence row 909

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 38751621

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro.
  16. Evidence row 910

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 20236042

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies.
  17. Evidence row 911

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 12823482

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.
  18. Evidence row 912

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 30414958

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.
  19. Evidence row 913

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 36583304

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation.
  20. Evidence row 914

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41875735

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.
  21. Evidence row 915

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Pediatric, adolescent, or developmental context mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40332343

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease.
  22. Evidence row 916

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41383775

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy.
  23. Evidence row 917

    Endocannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 24877594

    Evidence class: insufficient; Study design: Narrative or expert review. Source: What we know and do not know about the cannabinoid receptor 2 (CB2).
  24. Evidence row 918

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40791361

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases.
  25. Evidence row 919

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 40943579

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders.
  26. Evidence row 920

    2-AG modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 16086683

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.
  27. Evidence row 921

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41310604

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization.
  28. Evidence row 922

    THC modulates CB2; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 18247131

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.
  29. Evidence row 923

    Cannabinoids modulates CB2; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 32471272

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
  30. Evidence row 924

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 39538989

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling.
  31. Evidence row 925

    Cannabinoids modulates CB2; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: CB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms). PMID 41740200

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases.